HomeCONGRESS

CONGRESS

View Category
Day 4

SYMPLICITY FLEX: Renal sympathetic denervation in patients with resistant hypertension

Mild refractory hypertension patients were defined as those with daytime systolic BP 135-149 and diastolic BP 90-94...
solaci -
Learn More
Day 4

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences...
solaci -
Learn More
Day 3

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus...
solaci -
Learn More
Day 3

VELOCITY: Peritoneal hypothermia in patients undergoing primary angioplasty

There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal...
solaci -
Learn More
Day 3

TRANSLATE-ACS: One-year prasugrel versus clopidogrel after acute coronary syndrome

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute...
solaci -
Learn More
Day 3

ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination...
solaci -
Learn More
Day 3

BRIGHT: Bivalirudin versus heparin versus heparin plus tirofiban in primary angioplasty

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB...
solaci -
Learn More
Day 1

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the...
solaci -
Learn More